A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients
Neuro-Oncology Advances · 01.01.2023 · 5 (1)
DOI: 10.1093/noajnl/vdad036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 11.04.2023. Verfasst von Vicki Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EPA, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Lower-grade IDH mutant glioma patients frequently undergo malignant transformation (MT), with apparent worse prognosis. Many studies examine MT in mixed IDH status cohorts and define MT using imaging, not histopathology. Our study examines the timing, predictors, and prognostic implications of pathologically determined MT in a large, exclusively IDH mutant cohort.
Methods
We identified 193 IDH mutant lower-grade glioma patients at UCLA who received multiple surgeries. We examined the outcomes of pathologically determined MT patients.
Results
Time to MT is longer in grade 2 oligodendroglioma (G2 Oligo) than in grade 2 astrocytoma (G2 Astro) (HR = 0.46, P = .0007). The grade 3 astrocytoma (G3 Astro) to grade 4 astrocytoma (G4 Astro) interval is shorter in stepwise MT (G2 to G3 to G4 Astro) patients than in initial G3 Astro patients (P = .03). Novel contrast enhancement had 65% positive predictivity, 67% negative predictivity, 75% sensitivity, and 55% specificity in indicating pathologically defined MT. In G2 Astro, initial gross total resection delayed MT (HR = 0.50, P = .02) and predicted better overall survival (OS) (HR = 0.34, P = .009). In G2 Oligo, spontaneous MT occurred earlier than treated MT (HR = 11.43, P = .0002), but treatment did not predict improved OS (P = .8). MT patients (n = 126) exhibited worse OS than non-MT patients (n = 67) in All (HR = 2.54, P = .0009) and G2 Astro (HR = 4.26, P = .02).
Conclusion
Our study expands the understanding of MT to improve IDH mutant lower-grade glioma management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
- Department of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
- Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Förderung
- EPA
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
- American Cancer Society
Zitieren
APA
Liu, V., Wetzel, E. A., Eldred, B. S. C., Zapanta Rinonos, S., Prins, T. J., Khanlou, N., Liau, L. M., Chong, R., Nghiemphu, P. L., Cloughesy, T. F., Ellingson, B. M., & Lai, A. (2023). A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad036
Vancouver
Liu V, Wetzel EA, Eldred BSC, Zapanta Rinonos S, Prins TJ, Khanlou N, et al. A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad036
BibTeX
@article{Liu2023,
author = {Liu, Vicki and Wetzel, Ethan A and Eldred, Blaine S C and Zapanta Rinonos, Serendipity and Prins, Terry J and Khanlou, Negar and Liau, Linda M and Chong, Robert and Nghiemphu, Phioanh L and Cloughesy, Timothy F and Ellingson, Benjamin M and Lai, Albert},
title = {A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients},
journal = {Neuro-Oncology Advances},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/noajnl/vdad036}
}
EUVIMED